Results 161 to 170 of about 6,916,201 (263)

ROS/pH‐Responsive Phenylboronic Acid–Chitosan Nanoparticles Improve Silymarin‐Mediated Hepatoprotection After Hepatectomy With Gut‐Liver Axis‐Associated Responses

open access: yesAdvanced Science, EarlyView.
Bioactive phenylboronic acid–chitosan nanoparticles enable responsive silymarin delivery for post‐hepatectomy liver protection. The nanoplatform integrates antioxidant and antibacterial functions, improves hepatic recovery, and is associated with coordinated shifts in gut microbiota, metabolites, cytokines, and hepatic proteomic pathways, suggesting a ...
Jinjin Tong   +9 more
wiley   +1 more source

Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer. [PDF]

open access: yesESMO Open, 2023
Martini G   +32 more
europepmc   +1 more source

Epigenetic Silencing of CYYR1 Promotes Lung Adenocarcinoma Progression Through TRIM21‐Dependent Regulation of HMMR Stability

open access: yesAdvanced Science, EarlyView.
CYYR1 as an epigenetically dysregulated tumor‐suppressive factor that influences oncoprotein stability through TRIM21‐dependent HMMR regulation and reveals a potential therapeutic vulnerability in CYYR1‐deficient LUAD. The graphical illustration was created using FigDraw (www.figdraw.com).
Fengsheng Dai   +15 more
wiley   +1 more source

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer. [PDF]

open access: yesBMC Cancer, 2023
Divoux J   +25 more
europepmc   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

open access: yesAdvanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen   +10 more
wiley   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

open access: yesHepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode   +16 more
wiley   +1 more source

Patient-derived Organoids in Bladder Cancer: Opportunities and Challenges.

open access: yes
Background And Objective Bladder cancer (BLCa) remains a prevalent malignancy with high recurrence rates and limited treatment options. In recent years, patient-derived organoids (PDOs) have emerged as a promising platform for studying cancer biology and
Seiler, Roland   +3 more
core   +1 more source

Platycodon grandiflorus–Derived Nanovesicles Sensitize Gastric Cancer to T Cell Killing via Ferroptosis‐Driven Membrane Mechanical Remodeling

open access: yesAdvanced Science, EarlyView.
Plant‐derived nanovesicles from Platycodon grandiflorus act as bioactive lipid delivery platforms that transport γ‐linolenic acid into gastric cancer cells. This lipid cargo promotes ferroptotic lipid peroxidation, remodels membrane mechanics, and increases tumor‐cell susceptibility to cytotoxic T‐cell attack.
Jian Wu   +9 more
wiley   +1 more source

Comparative characterization of OncoPro™ and Wnt-based media reveals distinct phenotypic and pharmacologic states in patient-derived tumor organoids. [PDF]

open access: yesExp Hematol Oncol
Seghers S   +19 more
europepmc   +1 more source

Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens. [PDF]

open access: yesCancer Immunol Immunother, 2023
Parikh AY   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy